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Abstract
IL-11 is multifunctional cytokine whose physiological role in the lungs during pulmonary tuberculosis (TB) is poorly
understood. Here, using in vivo administration of specific antibodies against IL-11, we demonstrate for the first time that
blocking IL-11 diminishes histopathology and neutrophilic infiltration of the lung tissue in TB-infected genetically
susceptible mice. Antibody treatment decreased the pulmonary levels of IL-11 and other key inflammatory cytokines not
belonging to the Th1 axis, and down-regulated IL-11 mRNA expression. This suggests the existence of a positive feedback
loop at the transcriptional level, which is further supported by up-regulation of IL-11 mRNA expression in the presence of
rIL-11 in in vitro cultures of lung cells. These findings imply a pathogenic role for IL-11 during the early phase of
Mycobacterium tuberculosis-triggered disease in a genetically susceptible host.
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Introduction
IL-11 is multifunctional cytokine with hematopoietic, immuno-
modulatory, and epithelial cell protective activities [1]. It is a
member of the IL-6 cytokine family which includes cytokines that
share the use of the gp130 molecule in their receptor complexes
[2,3]. In several clinical and experimental studies, IL-11 displayed
anti-inflammatory activity [4–7], although its over-expression may
have a significant pro-inflammatory effect [8]. IL-11 augmented
bone marrow recovery and platelet production, down-regulated
pro-inflammatory type 1 cytokines, and has been approved for the
human use for corresponding indications [1,9,10]. In the lungs,
IL-11 was shown to be produced by epithelial cells, fibroblasts,
smooth muscle cells and antigen-presenting cells in response to
different stimuli, including respiratory viruses [11–14]. Using the
ovalbumin-induced asthma model in transgenic and IL-11Ra-
disrupted mice, it was demonstrated that IL-11 is involved in
regulation of such Th2-type pulmonary responses as eosinophilic
inflammation, mucus metaplasia and IL-13 production, without
shifting the response towards Th1 inflammation [15–17].
The role of IL-11 during pulmonary tuberculosis (TB) and
accompanying lung inflammation is poorly understood. In vitro
studies from our laboratory demonstrated that the important
producers of IL-11 are interstitial lung macrophages, and that the
level of mRNA for IL-11 in these cells differs substantially between
mouse strains, being higher in TB-susceptible I/St compared to
TB-resistant A/Sn mice [18]. More recently, using infected (I/
St6A/Sn) F2 hybrids segregating for the level of TB severity, it
was demonstrated that the individual levels of IL-11 mRNA in the
lung tissue correlated inversely with rapid body weight loss, the
phenotype characteristic for Mycobacterium tuberculosis-triggered
disease [19]. However, there was no direct physiologic evidence
that disease progression and immune responses in the lungs could
be altered by manipulating IL-11 production in vivo. Here, we
show that blocking endogenous IL-11 with specific antibodies in
vivo attenuates the severity of TB in genetically susceptible I/St
mice. Moreover, we demonstrate that antibody treatment not only
decreases the lung IL-11 content, but also down-regulates its
mRNA expression, suggesting the existence of a positive feed-back
loop at the transcriptional level, which is supported by in vitro
experiments.
Results and Discussion
Rapid IL-11 response in the lungs of genetically
susceptible mice after TB challenge and therapeutic
effect of the anti-IL-11 treatment
Earlier we found that isolated and cultured interstitial lung
macrophages from TB-susceptible I/St mice produced significant-
ly more IL-11 than their counterparts from TB-resistant A/Sn
mice [18]. Since numerous cell types are capable of producing this
cytokine in the lungs [11–14,18], it was useful to evaluate whether
or not TB-susceptible and resistant mice differed in the expression
of IL-11 in vivo at the whole-organ level before and after TB
infection. Assessment of mRNA extracted from the whole lungs of
mice of the two strains by DNA microarray provided a ,5-fold
increase (2
DCt=2.3) in il11 expression in TB-infected compared to
naı ¨ve I/St mice, whereas its expression in A/Sn mice did not
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DCt=0.7). To address this issue more
precisely, we compared the expression level of the il11 gene in the
lungs before and after TB challenge using qrt-PCR. At the whole-
organ level, naı ¨ve A/Sn mice produced slightly more IL-11
mRNA compared to naı ¨ve I/St mice, which may reflect its
production by cells other than lung macrophages and/or the
difference between in vivo and in vitro systems. However, at 2 weeks
post challenge, the levels of IL-11 mRNA remained the same in
the lungs of A/Sn mice, but increased ,10-fold (P,0.01) in I/St
mice (Fig. 1), suggesting an altered control of the infection-induced
early IL-11 production in genetically susceptible animals.
Importantly, the different kinetics of il11 expression in the two
mouse strains can not be explained by a more rapid accumulation
of mycobacteria (stimulus) in the lungs of I/St mice, since there is
no difference in mycobacterial growth between I/St and A/Sn
mice until 3 weeks post challenge ([20], confirmed in this study,
data not shown). It is also unlikely that a rapid increase in IL-11
response is due to some specific features of I/St genetic
background: a reverse correlation between the level of IL-11
expression in the lungs and severity of early TB was demonstrated
in a big segregating population of (I/St6A/Sn) F2 mice with
highly diverse individual genetic compositions [19]. These
observations prompted us to perform blocking experiments in an
attempt to diminish the severity of the TB course in I/St mice.
Groups of I/St mice were infected and treated with either anti-
IL-11 antibodies or pre-immune globulin as described in Materials
& Methods, and mycobacterial loads in the lungs were compared
between groups at day 24 post challenge. As shown in Fig. 2A,
significantly fewer CFU were recovered from the lungs of anti-IL-
11-treated mice, indicating a beneficial effect of treatment. We
also compared the severity of lung pathology between experimen-
tal and control groups and found that anti-IL-11-treated animals
did not develop necrotizing and/or coalescing TB foci (Fig. 2C),
which were readily detected in a proportion of control animals
(Fig. 2B). This is an important observation, since both in humans
and animals areas of necrosis and surrounding acellular matrix
(rim structure) are primary sites for production of large numbers of
bacteria [21,22], which provides a good explanation for the
difference in CFU counts. A quantitative evaluation of pathology
demonstrated that significantly smaller areas of the lung tissue
were affected by inflammation in the experimental compared to
the control group (Fig. 2D).
Taken together, these results clearly demonstrate a detrimental
effect of the early IL-11 hyper-production in response to
mycobacteria and suggest its causative role in pathogenesis of M.
tuberculosis-triggered lung disease in mice.
Cellular infiltration and immune responses in the lungs
To find out how anti-IL-11 treatment alters infection-induced
cellular infiltration, we assessed the content of major immune cell
types in the lungs of infected mice. As shown in Table 1, the only
statistically significant difference between mice that received non-
immune rabbit globulin and anti-IL-11 antibodies was a reduced
neutrophil content in the latter group. There is ample evidence
that neutrophilic inflammation plays a detrimental role in
mycobacteria-induced pathology. We and others, using genetic
approaches, demonstrated deleterious rather than beneficial effects
of these early inflammatory cells in the course of chronic
mycobacterial infections [23–26]. The data presented herein add
to this line of evidence, demonstrating the role of IL-11 in
neutrophilia and providing an explanation for an early appearance
of necrotic zones in the lungs of control mice displayed in Fig. 1B.
As the granulomata mature, lung-infiltrating neutrophils die
rapidly and the sites of their accumulation are replaced by
necrotic zones [24].
We also assessed how the blocking of IL-11 influences the
production of major cytokines in the lungs of infected mice.
Treatment with anti-IL-11 antibodies significantly decreased the
level of IL-11 itself, as well as the levels of key pro-inflammatory
and immunoregulatory molecules – IL-6, TNF-a and MIP-2. On
the other hand, the Th1-shifted immune response was not affected
by the antibody administration: the prominent production of IL-
12 and IFN-c and the marginal to un-measurable production of
IL-10 and IL-4 (not shown) was equal in antibody-treated and
control mice (Fig. 3).
The question about IL-11 involvement in Th1/Th2 modulation
remains unresolved. For example, there is evidence in cell culture
systems that IL-11 can down-regulate IL-12 and IFN-c production
[27,28], but in vivo studies in gene knock-out and transgenic mice
demonstrated its capacity to down-regulate Th2 cytokine produc-
tion [11,17]. It is difficult to judge which activity, if any, might
predominate during natural, un-manipulated in vivo conditions.
The results of our blocking experiments in the mouse model of
pulmonary TB clearly demonstrate that IL-11 substantially
promotes lung inflammation but does not inhibit the Th1
response. It is quite possible that there is no general physiological
pattern of immune response regulation by IL-11, and that it is
dependent upon the biological context within which the effects of
IL-11 are assessed.
Autocrine regulation of IL-11 production at the
transcriptional level
Our data demonstrate that elevated lung IL-11 production
starts very early after infection, and that neutralization of IL-11
diminishes both lung pathology and production of key regulatory
cytokines. To find out whether a decrease in pulmonary IL-11, IL-
6, TNF-a and MIP-2 protein production at day 24 post challenge
was due to down-regulation of the expression of the corresponding
Figure 1. Two weeks after TB challenge the level of IL-11 mRNA
increases ,1 log in the lungs of TB-susceptible I/St but does
not change in TB-resistant A/Sn mice. Mean 6 SEM expression
level plotted against that of GABDT in 4 individual mice per group is
displayed (P,0.01, ANOVA, between naı ¨ve and infected I/St mice).
doi:10.1371/journal.pone.0021878.g001
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lung tissue of mice treated with either anti-IL-11 antibodies or
control globulin. To our surprise, the only factor whose lung
mRNA expression significantly decreased in anti-IL-11 treated
mice was IL-11 itself (Fig. 4A). This result suggested that IL-11
expression is regulated post-infection in an autocrine manner at
the translational level. On the other hand, no significant changes
at the mRNA expression level were observed for IL-6, TNF-a and
MIP-2, indicating that their decreased production in anti-IL-11-
treated mice may well be due to reduced inflammation compared
to control animals. To test the existence of a positive feed back
loop, we assessed the level of IL-11 mRNA in lung cells cultured in
the presence or absence of recombinant murine IL-11. As shown
in Fig. 4B, 12-h incubation of lung cells in the presence of 100 ng/
ml of rmIL-11 resulted in a significant increase in the il11 mRNA
levels compared to control cells, supporting our hypothesis.
Overall, our findings suggest that IL-11 production is rapidly
elevated and self-supported in the lungs of genetically susceptible
TB-infected mice. This promotes the development of early
inflammation with a substantial contribution by neutrophils
which, in turn, biases the response towards necrotic granuloma
formation, accompanied by accelerated mycobacterial multiplica-




Female mice of the I/StSnEgYCit strain (hereafter – I/St) aged
9–10 weeks were used. Compared to several inbred mouse strains,
including A/SnEgCit (A/Sn) also used in this study, these mice
display an extremely high level of susceptibility to TB, severity of
lung pathology and prominent infiltration of M. tuberculosis-infected
lung tissue with neutrophils, regardless to the dose and route of
challenge [23,24,30,31]. Mice were bred under conventional
conditions at the Animal Facilities of the Central Institute for
Tuberculosis (CIT, Moscow, Russia), in accordance with the
guidelines from the Russian Ministry of Health # 755, NIH Office
of Laboratory Animal Welfare (OLAW) Assurance #A5502.
Water and food were provided ad libitum. All experimental
procedures were approved by the CIT animal care committee
(IACUC protocols #2, 7, 8, 11, 13 approved on September 20,
2009).
Anti-IL-11 antibodies
Two conventional white rabbits were immunized with 0.05 mg
of recombinant murine (rm) IL-11 (Sigma, St-Louis, MA) in
incomplete Freund’s adjuvant (Sigma), thrice, subcutaneously,
with a 3-wk interval between injections. Before the first
immunization, animals were bled and their serum immunoglob-
ulin was affinity purified and depleted of anti-mycobacterial
activity using procedures identical to those described below for
immune sera. The mixed globulin preparation obtained from two
non-immune rabbits served as the autologous control for in vivo
administration. One month after the third immunization, animals
were bled, and the level of anti-IL-11 antibodies in their mixed
sera was assessed by indirect ELISA using rmIL-11 and immune
anti-rabbit IgG conjugate (Bio-Rad, Richmond, CA). Serum IgG
was isolated using Sepharose CL4B-protein A adsorbent (Phar-
macia, Uppsala, Sweden).
Normal rabbit immunoglobulin possesses an intrinsic anti-
mycobacterial activity which, after in vivo administration, could
modulate the course of mycobacterial infection [32]. To avoid
interference with their specific anti-IL-11 activity, immune and
non-immune preparations were depleted of anti-mycobacterial
activity using affinity chromatography. To this end, we prepared
an immune adsorbent of Mycobacterium tuberculosis H37Rv sonicate
bound to BrCN-activated Sepharose CL6B (Pharmacia, Uppsala,
Sweden), as described [33], and repeatedly absorbed immuno-
globulin preparations until the activity against mycobacterial
sonicate assessed by immune blotting was completely lost (data not
shown). Reactivity of the control and anti-IL-11 immunoglobulin
preparations was assessed in the ELISA format and by immune
blotting using rmIL-11 (Fig. 5A, B).











6/lobe Per cent 10
6/lobe Per cent 10
6/lobe Per cent 10
6/lobe Per cent 10
6/lobe
Control Ig 15.161.5 40.662.4 6.160.5 19.661.8 3.060.2 14.161.2 2.260.2 8.760.6 1.360.2 15.2±2.5 2.3±0.3
Anti-IL-11 12.861.3 40.762.3 5.260.5 19.461.2 2.560.4 19.962.6 2.660.3 9.160.6 1.260.1 8.4±1.2 1.1±0.2
P 0.278 .0.7 .0.5 0.384 .0.8 0.024
b
*Middle right lobes were individually isolated from two groups of mice (two independent experiments, exp. 1: N=7 and 7; exp. 2: N=9 and 10; total N=16control and
N=17 exp.), enzymatically disrupted, and single-cell suspensions analyzed by flow cytometry using FITC- or PE-labeled mAbs to the indicated surface markers. Results are
presented as summarized mean 6 SD for all animals.
aFor F4/80
+ macrophages and Ly-6G
+ PMN: per cent of the total cell count; for B- and T-lymphocytes: per cent of the population gated for the lymphocyte size.
Significant (Student’s t-test) difference in the neutrophil content between experimental and control groups is highlighted in bold.
bThe only statistically significant difference between mice that received control rabbit globulin and anti-IL-11 antibodies was a decrease in the lung neutrophil
infiltration in the latter group.
doi:10.1371/journal.pone.0021878.t001
Figure 2. Treatment with anti-IL-11 antibodies significantly attenuates the severity of TB in I/St mice. (A) ,3-fold decrease in lung CFU
counts compared to control animals. (B and C) Lung pathology in individual animals. None of anti-IL-11-treated mice developed necrotic TB foci
evident in control mice a, d and g (circled). (D) Statistical evaluation of the proportion of inflamed lung tissue. CFU counts and morphometry were
performed in all mice included in 2 independent experiments (total N=16 and 17 for experimental and control groups, respectively). Histology is
displayed for individual mice analyzed in one experiment (N=7 for each group).
doi:10.1371/journal.pone.0021878.g002
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At day 0, mice were infected with 10
3 CFU Mycobacterium
tuberculosis H37Rv (Pasteur) via intra-tracheal route exactly as
described previously [31]. At days 21, +2, +14, +17, +20 and +22
mice were injected peritoneally with 50 mg/mouse of either anti-IL-
11 (experiment) or pre-immune (control) purified rabbit immuno-
globulinpreparation.Twoindependent experimentsingroups of7–
10 controland experimental animals eachprovided almost identical
results, which were combined for the statistical analysis of the major
phenotypes.
CFU counts
Mice were sacrificed at day 24 post-challenge. Apical right lobes
from individual mice (in two experiments total N=17contr. and
N=18 exp.) were homogenized in 1 ml of sterile saline, and 0.1 ml
of serial 10-fold dilutions of homogenates were plated onto Dubos
agar. Colonies were counted after 18–20 days of incubation at
37uC.
Histopathology
Left lungs of individual mice were removed, inflated with 4%
formalin in PBS (pH=7.2) via the bronchus, and fixed in 4%
formalin for 24 h. The samples were processed, embedded in
paraffin, sectioned and stained with hematoxylin and eosin.
Morphometry was performed at the 637.5 magnification using
Axioskop 40 microscope and AxioVision 4.8.1.0 software (Carl
Zeiss, Berlin, Germany). The area of inflamed lung parenchyma,
excluding vessels and airways, was measured and calculated as a
percentage of the area of total lung parenchyma.
Cytokine mRNA quantification
Total RNA from the lower right lung lobes of individual mice
was isolated using the commercial SV Total RNA Isolation
System, and reverse transcription of mRNA was performed using
reagents and protocols from Promega, Madison, WI. To detect the
mRNA levels for a number of inflammation-related genes,
quantitative real-time RT-PCR (qrt-PCR) with cDNA was
performed using the iCycler iQ Multicolor Real-Time PCR
Detection System (BioRad, Hercules, CA), and specific primers,
TaqMan probes and reagents from Applied Biosystems (Foster
City, CA). Gene expression levels in the lung tissue of individual
mice were normalized to those of GAPDH. To quantify the results
Figure 4. Protein levels of IL-11 affect IL-11 mRNA expression. (A) In vivo administration of anti-IL-11 antibodies leads to a selective down-
regulation of IL-11 mRNA. The level of expression was quantified in 5 individual mice per group, using qrt-PCR and normalization against the level of
GAPDH expression. Results obtained in 1 of 2 similar experiments are expressed as mean 6 SEM (for IL-11 expression P=0.021, for other cytokines
P.0.05). (B) Introduction of 100 ng/ml rIL-11 in cultures of lung cells up-regulates the expression of IL-11 mRNA. Results of two similar experiments
are expressed as mean of 3 wells 6 SEM (P,0.01, ANOVA, compared to negative controls and cultures stimulated with 10 ng/ml IL-11).
doi:10.1371/journal.pone.0021878.g004
Figure 3. Anti-IL-11 antibody therapy decreases levels of IL-11
and pro-inflammatory factors in the lung tissue without
shifting the IL-12 – IFN-c/IL-10 balance. Cytokine contents in lung
homogenates were assessed by ELISA for 4 mice in each group. The
results of one of two similar experiments are displayed as mean 6 SEM.
doi:10.1371/journal.pone.0021878.g003
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was used exactly as described in [34], with the expression of the
results as mean fold increase 6 SEM for groups of 4 mice each.
To assess the ability of rIL-11 to up-regulate its own mRNA
production, lung cell suspensions were prepared as described in
[31], and cultured in RPMI-1640 medium containing 5% FCS
and standard supplements (all components – HiClone, HiClone,
Logan, UT, USA). Lung cells were cultured in 6-well plates
(Costar, Badhoevedorp, The Netherlands) at 1.5610
6 cells/ml in
the absence or presence of 10 ng/ml and 100 ng/ml rmIL-11
(ImmunoTools, Friesoythe, Germany) for 12 h before RNA was
isolated, reversely transcribed, and il11 expression was assessed
with normalization to that of GAPDH. Two independent
experiments, performed with mixtures of RNA from 3 I/St mice
each, provided similar results.
Flow cytometry and cytokine ELISA
Middle right lobes were individually isolated, enzymatically
disrupted as described in [31], and single-cell suspensions analyzed
by flow cytometry using FITC- or PE-labeled mAbs to the
indicated surface markers (Table 1). Results are presented as
summarized mean 6 SEM for all animals.
To measure cytokine contents, the rest of each sample was
centrifuged, and the pellets frozen at 270uC until assessed. The
thawed samples from 4 mice in each group were diluted in 2 ml of
PBS, debris removed by centrifugation at 500 g, and the cytokine
content assessed in ELISA format using the ELISA kits for IL-6,
IL-10, IL-12, MIP-2, TNF-a and IFN-c purchased from
PharMingen, San-Diego, CA, and for IL-11 purchased from
R&D Systems, Minneapolis, MI, according to the manufacturers’
instructions.
Statistical Analyses
One-tail analysis of variance (ANOVA) and Student’s t-test
were used as indicated in figure legends and table footnotes.
P,0.05 was considered statistically significant.
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